NeurAxon Pharma Inc is a privately owned semi-virtual pharmaceutical company developing new chemical entities (NCEs) for the treatment of neurological disorders.
NeurAxon has developed a platform of selective inhibitors of the nitric oxide synthase (NOS) enzyme family, the enzyme which produces nitric oxide (NO).
As the first company to be able to specifically target and inhibit the individual isozymes (nNOS, eNOS, iNOS), NeurAxon can avoid any of the effects of blood pressure usually associated with eNOS providing the benefits of nNOS and iNOS alone or in combination as required.
NO has been implicated in a wide variety of neurological disorders from migraine through to neurodegeneration. NeurAxonís selective NOS inhibitors may be especially suited to neurodegenerative diseases as a transformative symptomatic and disease modifying treatment. Parkinsonís Disease (PD) in particular may be particularly amenable to NOS based therapeutics.
NeurAxon Pharma Inc has developed the NOS technology under an exclusive license from Knight Theraputics.